Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Operating Expenses (2017 - 2025)

Historic Operating Expenses for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $44.9 million.

  • Puma Biotechnology's Operating Expenses fell 2319.59% to $44.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $178.4 million, marking a year-over-year decrease of 1550.08%. This contributed to the annual value of $199.5 million for FY2024, which is 172.17% down from last year.
  • According to the latest figures from Q3 2025, Puma Biotechnology's Operating Expenses is $44.9 million, which was down 2319.59% from $45.8 million recorded in Q2 2025.
  • Puma Biotechnology's Operating Expenses' 5-year high stood at $78.0 million during Q1 2021, with a 5-year trough of $42.0 million in Q1 2025.
  • Its 5-year average for Operating Expenses is $52.2 million, with a median of $48.5 million in 2021.
  • As far as peak fluctuations go, Puma Biotechnology's Operating Expenses plummeted by 4042.4% in 2022, and later soared by 2299.97% in 2024.
  • Over the past 5 years, Puma Biotechnology's Operating Expenses (Quarter) stood at $48.5 million in 2021, then increased by 14.7% to $55.7 million in 2022, then increased by 3.09% to $57.4 million in 2023, then fell by 20.33% to $45.7 million in 2024, then decreased by 1.77% to $44.9 million in 2025.
  • Its Operating Expenses was $44.9 million in Q3 2025, compared to $45.8 million in Q2 2025 and $42.0 million in Q1 2025.